TheraRadar

AB Science

Pre-Approval PRO BETA
24
Total Trials
22
Phase 3
6
Phase 2
3
Recruiting
391
Score

Pipeline by Phase

Phase 3
22
Phase 2
6
Phase 1
1

Therapeutic Focus

Alzheimer Disease Amyotrophic Lateral Sclerosis (ALS) Gastrointestinal Stromal Tumors Asthma Acute Myeloid Leukemia Refractory

Clinical Trials (24)

NCT03127267 Phase 3 RECRUITING

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Started: 2/2/2021

NCT05564169 Phase 3 NOT YET RECRUITING

Masitinib in Patients With Mild Alzheimer's Disease

Started: 6/1/2026

NCT07174492 Phase 3 NOT YET RECRUITING

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

Started: 1/1/2026

NCT05441488 Phase 3 ACTIVE NOT RECRUITING

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Started: 6/28/2022

NCT01872598 Phase 3 COMPLETED

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Started: 1/1/2012

NCT03761225 Phase 3 COMPLETED

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Started: 9/1/2014

NCT00812240 Phase 3 TERMINATED

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Started: 1/1/2009

NCT01449162 Phase 3 COMPLETED

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Started: 1/1/2011

NCT03766295 Phase 3 COMPLETED

Masitinib Plus Gemcitabine in Pancreatic Cancer

Started: 7/1/2014

NCT03771040 Phase 3 COMPLETED

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Started: 12/1/2016

NCT01694277 Phase 3 COMPLETED

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Started: 4/1/2012

NCT01280565 Phase 3 TERMINATED

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Started: 1/1/2011

NCT01433497 Phase 3 COMPLETED

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Started: 8/1/2011

NCT00814073 Phase 3 COMPLETED

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Started: 12/1/2008

NCT02605044 Phase 3 TERMINATED

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Started: 1/1/2014

NCT01470131 Phase 3 TERMINATED

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Started: 5/1/2011

NCT00789633 Phase 3 COMPLETED

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Started: 11/25/2008

NCT02009423 Phase 3 TERMINATED

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Started: 7/1/2015

NCT02588677 Phase 2 COMPLETED

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Started: 4/1/2013

NCT03556956 Phase 2 COMPLETED

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Started: 7/1/2015

NCT02490488 Phase 2 COMPLETED

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Started: 4/1/2014

NCT01410695 Phase 2 TERMINATED

Masitinib in Refractory Active Rheumatoid Arthritis

Started: 7/1/2011

NCT01506336 Phase 2 COMPLETED

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Started: 10/1/2008

NCT05211570 Phase 1 RECRUITING

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Started: 6/1/2022

Drug Candidates

Placebo Masitinib (4.5) Standard of care Masitinib 4.5 mg/kg/day Riluzole (100 mg) AB8939 Venetoclax Masitinib (6.0) Riluzole Masitinib
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 12/15/2020
Trials (12 months): 2
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.